See press release: May 2013: biopharma companies acceleron and shire announced they stopped development of ace-031 for duchenne muscular dystrophy. Ace-031 is an inhibitor of myostatin and other related, naturally occurring proteins that limit muscle growth. In feb 2011, clinical trials of the drug were halted because some participants experienced minor nosebleeds, gum bleeds and/or dilation of skin vessels.
Answered 9/28/2016
5k views
8 doctors weighed in across 2 answers
A doctor has provided 1 answer
2 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question